Statutory scheme to control cost of branded medicines
Read the full outcome
Detail of outcome
The government has published its response to the consultation on proposed changes to the statutory scheme that controls the prices of branded health service medicines.
The government made some changes to its proposals in response to issues and concerns raised by respondents. These are set out in the response document.
The finalised regulations, explanatory memorandum and impact assessment have been published.
Original consultation
Consultation description
The government is consulting on proposals to amend the statutory scheme that controls the prices of branded health service medicines. This builds on a previous consultation run in 2015.
The aim is to achieve alignment with the current voluntary pharmaceutical price regulation scheme (PPRS), agreed in 2014.
The main proposals in the consultation are:
- the introduction of a payment system similar to that in the 2014 PPRS
- changes to the provisions on maximum prices, including removing the requirement for a 15% price cut
- changes to the information requirements placed on companies
Draft regulations and a draft impact assessment are published alongside this consultation.
Documents
Updates to this page
Published 23 August 2017Last updated 9 March 2018 + show all updates
-
Consultation response published.
-
First published.